MANGOCEUTICALS, INC. (MGRX) Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Sector: Services-Misc Health & Allied Services, NEC
Industry: Medical - Healthcare Information Services
Mangoceuticals, Inc. NASDAQ:MGRX Healthcare · Medical - Healthcare Information Services
Mkt Cap $3.56M
EV -
SI 0.3%
Net Cash/Sh -
CLOSED · Nov 17 -0.19%$0.1600 CLOSED · Nov 17 Prev close $0.1603 -0.19%Close $0.1600 +3.37%AH close $0.1654 VOL 409K $ Vol $65K RVOL 0.52x
Mkt Cap $3.56M
EV -
VOL 409K sh
$ Vol $65K
RVOL 0.52×
SI 0.3%
Net Cash/Sh -
Press Release
Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform
Mangoceuticals announced a partnership with T7X to issue up to 1,000,000 shares of tokenized Series D Cumulative Convertible Preferred Stock at $10.00 per share, for gross proceeds of up to $10 million, in what it says would be the first security issued by a Nasdaq-listed company on the T7X platform. The preferred carries an 8% cumulative annual dividend on the $10.00 stated value, payable quarterly when declared. No common stock is issued at closing; conversion begins three years after issuance at a fixed price equal to 300% of the pre-qualification 10-day VWAP, subject to a floor price.
• 5d ago AI analysis › Press Release
Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
Mangoceuticals closed an approximately $500,000 registered direct offering priced at $0.75 per unit, roughly a 74% premium to its referenced recent close of $0.43. Each unit consists of one share of common stock plus one warrant. The financing follows $2.5 million in strategic investment commitments at subsidiary MangoRx IP Holdings, of which $1.75 million has been received, with the remaining $750,000 due by November 28, 2026. The subsidiary-level funding did not require issuance of parent common stock.
• 1mo ago AI analysis › Press Release
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Mangoceuticals secured a $2.5 million strategic investment directly into its subsidiary MangoRx IP Holdings, with an initial $1.75 million tranche already received. Investors purchase an aggregate 25% membership interest in two tranches, and no MGRX common stock, warrants, or parent securities are being issued, leaving the public capitalization untouched. The capital funds commercialization of the MGX-0024 antiviral patent portfolio (U.S. Patent No.
• 1mo ago AI analysis › Press Release ● Major
Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
Nuclea Energy, the target of Mangoceuticals (MGRX), has agreed to acquire the advanced nuclear assets of Moltex Energy, which is currently in administration. The acquisition includes 80 patents across 9 families covering the SSR-W reactor and WATSS spent-fuel recycling technologies, backed by over C$96 million in prior development funding.
• 3mo ago AI analysis › Press Release
Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
Mangoceuticals announced that its pending merger partner, Nuclea Energy, has entered into a definitive agreement to acquire advanced nuclear technology assets from Moltex Energy. The asset-led transaction adds the SSR-W advanced reactor, WATSS spent fuel recycling technology, and a portfolio of 80 patents to Nuclea's Morpheus microreactor platform.
• 3mo ago AI analysis › Press Release
Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
Nuclea Energy, which is merging with MGRX, signed a non-binding MOU with Bitcoin miner New Mining Co. to evaluate deploying Nuclea's modular reactors for behind-the-meter power. The phased evaluation targets an initial 30 MWe of operational load, with a path toward 100 MWe of cumulative capacity as New Mining's infrastructure expands.
• 3mo ago AI analysis › Press Release
Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
Nuclea Energy, Mangoceuticals’ pending merger partner, signed a non-binding MOU with Bitcoin miner New Mining Co. to evaluate deploying the Morpheus microreactor for behind-the-meter power. The evaluation targets an initial phase for 30 MWe of operational load, with a scalability path toward a cumulative capacity of 100 MWe.
• 3mo ago AI analysis › Press Release
Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
Nuclea Energy USA, a subsidiary of the company merging with MGRX, signed an MOU with the Utah Office of Energy Development to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab. The partnership aims to facilitate engagement with the DOE and NRC to advance the Morpheus microreactor, a lead-cooled system scalable from 3.5 MWe to 50 MWe.
• 3mo ago AI analysis › Press Release
Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
Nuclea Energy, Mangoceuticals' pending merger partner, signed a memorandum of understanding with the Utah Office of Energy Development to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab. The agreement aims to advance Nuclea's Morpheus microreactor, a lead-cooled system scalable from 3.5 MWe to 50 MWe, by supporting engagement with the DOE and NRC.
• 3mo ago AI analysis › Press Release
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
Mangoceuticals secured a 180-day extension from Nasdaq to regain compliance with the minimum bid price rule, giving the company until February 1, 2027, to maintain a closing price above $1.00 for 10 consecutive business days. The company continues to advance a definitive business combination with Nuclea Energy, aiming to pivot from men's health telemedicine to advanced nuclear technology development. CEO Jacob D.
• 3mo ago AI analysis › Press Release ● Critical
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
Mangoceuticals (MGRX) entered into a definitive business combination agreement with Nuclea Energy, a developer of lead-cooled microreactors, in a transaction that will leave Nuclea shareholders with approximately 96% ownership of the combined company. The deal marks a pivot from men's health telemedicine to advanced nuclear power, targeting the growing demand for carbon-free electricity from AI data centers and remote sites.
• 3mo ago AI analysis › Press Release ● Major
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
Mangoceuticals signed a definitive agreement to amalgamate with Nuclea Energy, a developer of the lead-cooled Morpheus microreactor, marking a strategic pivot into the advanced nuclear sector. The transaction, which requires stockholder and Nasdaq approval due to issuance limits, aims to capitalize on surging power demand from AI data centers and favorable policy support like the ADVANCE Act.
• 3mo ago AI analysis › Press Release ● Major
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
globenewswire.com • 8mo ago Press Release ● Major
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
globenewswire.com • 8mo ago Press Release ● Major
Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
globenewswire.com • 8mo ago Press Release ● Critical
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
globenewswire.com • 8mo ago Press Release
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements
globenewswire.com • 10mo ago Press Release
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
globenewswire.com • 10mo ago Press Release
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
globenewswire.com • 10mo ago 1 law-firm class-action alert